Oxandrolone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Oxandrolone

Oxandrolone (Oxandrin) is an anabolic steroid created by Searle Laboratories under the trademark Anavar, and introduced into the US in 1964. It is taken orally, and unlike other steroids delivered in this manner, most of which are Class II steroids, the majority of its effects are due to reaction with the androgen receptor. In sufficient dosage, Oxandrolone is highly likely to bind well with the receptor, and is therefore a Class I steroid, while having few other side-effects. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

The drug was prescribed for a number of medical disorders causing involuntary weight loss, in order to promote muscle regrowth. It had also been shown to be partially successful in treating cases of osteoporosis. However, in part due to bad publicity from its illegal use by bodybuilders, Oxandrolone was discontinued by Searle Laboratories in 1989. It was picked up by Bio-Technology General Corporation who, following successful clinical trials in 1995, released it under the tradename Oxandrin. It was approved for orphan drug status by the FDA in treating alcoholic hepatitis, Turner's syndrome, and weight loss caused by HIV. In addition, the drug has shown positive results in treating anaemia and hereditary angioedema. Clinical studies however have shown links between prolonged use of the drug and problems of liver toxicity similar to those found with other 17α-alkylated steroids. Even in small dosages, many users reported gastro-intestinal problems such as bloating, nausea, and diarrhoea.

Before the Controlled Substances Act was passed to restrict the production, sale, and usage of anabolic steroids, Oxandrolone's characteristics lent itself well towards use by female athletes. Its specificity targeting the androgen receptor meant that, unlike many other steroids, it had not been reported to cause stunted growth in younger users, and at typical dosage rarely caused noticeable masculinising effects outside of stimulating muscle growth. In addition, Oxandrolone does not aromatise at any dosage, and is not easily metabolised into DHT or oestrogen. As such, a typical dose of 20-30 mg provided elevated androgen levels for up to eight hours. To increase effectiveness, bodybuilders typically "stacked" the drug with others such as Dianabol, further enhancing body mass gain.

Read more at Wikipedia.org


[List your site here Free!]


Hypovitaminosis D in pediatric burn patients
From Nutrition Research Newsletter, 6/1/04

Catabolism is increased after burn injury, characterized by significant loss of body protein and bone. Long-term consequences include growth arrest in children, low bone mineral density, and increased incidence of fracture.

Vitamin D is an important nutrient in children due to its role in bone formation during growth and development. It facilitates intestinal absorption of calcium and is required for calcium and phosphorus homeostasis. The prevalence of vitamin D insufficiency, its etiology and associated sequelae among acutely injured burn patients is unknown. Therefore, a recent study examined vitamin D and endocrine status, as well as the effect of anabolic agents, in acutely injured pediatric patients who had sustained burns in excess of 25% total body surface area (TBSA).

Sixty-nine patients with a mean TBSA burn of 50.6% and full thickness injury of 41.3% were studied. Subjects ranged in age from 0.6 yr to 18 yr. Morning blood samples were obtained weekly for serum 25-hydroxyvitamin D (D25), 1,25-dihydroxyvitamin D (D1,25), albumin, cortisol, triodothyronine (T3), tetraiodothyronine (T4), thyroid stimulating hormone (TSH) and parathormone (PTH). Exogenous vitamin D intake was not controlled in this study. Patients consumed vitamin Dad lib from an oral diet, plus they typically received twice the RDA of vitamin D per liter of tube feeding. Hypovitaminosis D was assessed by dividing patients into three diagnostic categories according to their serum vitamin D concentrations: those with adequate vitamin D25 status (>37.4 umol/L) or D 1,25 (>38.8 pmol/L), those with low vitamin D (20-37.3 nmol/L or D 1,25 (20.8-38.8 pmol/L)and those with very low serum vitamin D (<20 umol/L for D25, < 20.8 pmol/L for D1,25).

A total of 280 morning blood samples of D25 and D 1,25 demonstrated that 45% and 26.2% were low and 8.9% and 11% were very low, respectively. At least one low D25 or D1,25 level occurred in 62.3% of all children. Very low serum vitamin D levels were noted in 23.2% of all patients. There was an increased incidence of hyperparathyroidism in patients with very low serum D25. Vitamin D25 and D 1,25 levels were lower in subjects with larger burns or inhalation injury, as well as those treated with thyroxine or oxandrolone. Serum albumin, cortisol, T4, and TSH were not correlated with concentration of vitamin D.

Demonstration of a high incidence of low serum vitamin D indicates vitamin D status may be significantly compromised in burned children. One reason why this may be true is that serum albumin is the major binding protein of D1,25. Serum albumin levels decrease and remain low for long periods after thermal injury. However, there was no relationship found between albumin and D 1,25 in this study. It is also conceivable that the bum wound and scarring and also a lack of sunlight exposure may limit cutaneous vitamin D biosynthesis. Further studies should be conducted to determine whether larger doses of vitamin D, earlier initiation of treatment or perhaps a different form of vitamin D may be required to obtain improvements in outcome measures postburn.

Michele M. Gottschlich, Theresa Mayes, Jane Khoury, and Glenn D. Warden, Hypovitaminosis D in acutely injured pediatric bum patients, JADA 104(6): 931-934 (June 2004) [Address correspondence to: Michele M. Gottschlich, PhD, RD, Shriners Hospitals for Children, Nutrition Services, 3229 Burnet Ave, Cincinnati, OH 45229. E-mail: mgottschlich@shrinenet.org]

COPYRIGHT 2004 Frost & Sullivan
COPYRIGHT 2004 Gale Group

Return to Oxandrolone
Home Contact Resources Exchange Links ebay